$27.98
+1.71%Oct 14, 2026, 20:01 UTC
Lakefront Biotherapeutics completed the sale of its early-stage cell therapy pipeline to Armed Cell Therapeutics.
Source:Oct 13, 2026, 20:01 UTC
Lakefront Biotherapeutics repurchased 126,322 of its own shares for €3,317,407.94 under its repurchase program.
Source:Oct 6, 2026, 20:01 UTC
Lakefront Biotherapeutics repurchased 117,437 of its shares between September 28 and October 2, 2026, through a discretionary mandate to an independent financial intermediary.
Source:Sep 29, 2026, 20:01 UTC
Lakefront Biotherapeutics NV repurchased 106,060 of its own shares between September 21 and September 25, 2026 under its repurchase program announced on June 9, 2026.
Source:Sep 22, 2026, 20:01 UTC
Lakefront Biotherapeutics NV repurchased 108,679 of its own shares between September 14 and September 18, 2026 under its repurchase program announced on June 9, 2026.
Source:Sep 15, 2026, 20:01 UTC
Lakefront Biotherapeutics NV repurchased 125,517 of its own shares for about €3.0 million between September 7 and September 11, 2026 under its repurchase program announced on June 9, 2026.
Source:Sep 8, 2026, 20:02 UTC
Lakefront Biotherapeutics NV repurchased 132,014 of its own shares between August 31 and September 4, 2026, under its buyback program announced on June 9, 2026, for a total of €3,279,463.42.
Source:Sep 1, 2026, 20:01 UTC
Lakefront Biotherapeutics NV repurchased 127,796 of its own shares between August 24 and August 28, 2026, under its buyback program announced on June 9, 2026, via a discretionary mandate to an independent intermediary.
Source:Aug 25, 2026, 20:01 UTC
Lakefront Biotherapeutics NV repurchased 117,471 of its own shares between August 17 and August 21, 2026, under its buyback program announced on June 9, 2026, via a discretionary mandate to an independent intermediary.
Source:Aug 24, 2026, 20:01 UTC
The U.S. FDA granted Orphan Drug Designation to gamgertamig for the treatment of pemphigus, as announced by Lakefront Biotherapeutics NV on 24 August 2026.
Source:Aug 24, 2026, 20:01 UTC
Lakefront Biotherapeutics NV received a transparency notification from Bank of America regarding a change in its shareholding.
Source:Aug 18, 2026, 20:01 UTC
Lakefront Biotherapeutics NV repurchased 107,871 of its own shares between August 10 and August 14, 2026, under its buyback program announced on June 9, 2026, for a total of €2,604,002.56.
Source:Jul 29, 2026, 00:00 UTC
Fortrea Holdings Inc. appointed David Smith as Interim Chief Financial Officer and principal financial officer, effective July 27, 2026.
Jun 23, 2026, 20:01 UTC
Lakefront Biotherapeutics NV repurchased 77,667 of its own shares between 15 June 2026 and 19 June 2026 under a buyback program announced on 9 June 2026.